Kyverna Therapeutics (KYTX) Income towards Parent Company (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Income towards Parent Company data on file, last reported at -$74.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 62.83% year-over-year to -$74.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$209.0 million (down 22.46% YoY) and the FY2025 annual result came in at -$204.6 million, down 56.97% from the prior year.
• Income towards Parent Company eased to -$74.2 million in Q1 2026, from -$37.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$11.7 million in Q1 2023 to a low of -$74.2 million in Q1 2026.
• A 4-year average of -$36.1 million and a median of -$40.4 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company plunged 203.32% — and 2025, when it gained 6.66%.
• Tracing KYTX's Income towards Parent Company over 4 years: stood at -$20.6 million in 2023, then tumbled by 95.9% to -$40.4 million in 2024, then grew by 6.66% to -$37.7 million in 2025, then sank by 96.55% to -$74.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$74.2 million (Q1 2026), -$37.7 million (Q4 2025), and -$52.8 million (Q3 2025), per Business Quant data.